ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1586531
This article is part of the Research TopicInnovative Drug Combinations for Enhanced Solid Tumor Treatment EfficacyView all 9 articles
Outstanding Treatment Success of Pembrolizumab and Bevacizumab Combination Therapy in First-line Treatment of Cervical Sarcomatoid Carcinoma: A Rare Case Report
Provisionally accepted
- Shenzhen Traditional Chinese Medicine Hospital, Shenzhen ，Guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cervical lesions of sarcomatoid carcinoma are very rare, and there are still no reports of any targeted drugs applied in this rare tumor. In this report, we document a patient with stage IVA sarcomatoid carcinoma of the cervix, according to the FIGO staging system. The genetic testing of the patient’s tumor tissue indicated the expression of PD-L1. This finding is significant as it suggests that the patient may be a candidate for immunotherapy. Consequently, the patient was administered a combination therapy consisting of pembrolizumab and bevacizumab. After 2 cycles of treatment, there was a marked reduction in tumor volume and the patient did not experience any side effects. Since then, the patient has continued to receive the regimen and the tumor has continued to shrink. Ultimately, after 10 courses of treatment with immune checkpoint inhibitors and anti-angiogenic drugs, the PET-CT scan showed complete disappearance of the tumor, with no evidence of cancer throughout the body. Subsequently, the patient continued to receive maintenance therapy with the same regimen, with regular follow-up evaluations. No recurrence was detected until 13 months later, when a MRI scan revealed tumor recurrence. The combination of a PD-1 inhibitor with a drug that promotes tumor vascular normalization has shown promise in treating advanced cervical sarcomatoid carcinoma. We are the first to report the use of this combination regimen in this rare tumor, where previously reported treatment has been with chemotherapy agents. In addition, the level of PD-L1 expression could serve as a potential biomarker to predict the response to immunotherapy in patients with advanced sarcomatoid carcinoma of the cervix. In this manuscript, we report a case of a patient who achieved a transient recurrence-free survival period through combined therapy (although recurrence eventually occurred), with a progression-free survival exceeding 13 months and an overall survival exceeding 22 months (as of the last follow-up, the patient was receiving palliative care only). Our case highlights the efficacy of immunotherapy in combination with anti-angiogenic targeted therapy for the treatment of sarcomatoid carcinoma of the cervix.
Keywords: sarcomatoid carcinoma, cervix, pabolizumab, bevacizumab, PD-L1 SCC, sarcomatoid carcinoma of the cervix, WHO,World Health Organization, ICIs, Immune checkpoint inhibitors, PD-L1-positive, programmed death-ligand 1-positive, ICI, immune checkpoint inhibitor, PD-l, programmed cell death protein 1, VEGF, vascular endothelial growth factor, MRI, magnetic resonance imaging
Received: 03 Mar 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Zhang, LI, Huang, Yang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ming-Zi Zhang, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen ，Guangdong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.